Jupiter Topco LLC Makes New $69.40 Million Investment in Medpace Holdings, Inc. $MEDP

Jupiter Topco LLC acquired a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) in the second quarter, Holdings Channel.com reports. The firm acquired 130,948 shares of the company’s stock, valued at approximately $69,402,000.

Several other institutional investors and hedge funds have also modified their holdings of the stock. BlackRock Inc. purchased a new stake in shares of Medpace in the second quarter worth about $1,323,047,000. AQR Capital Management LLC raised its position in shares of Medpace by 31.6% in the fourth quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company’s stock worth $758,061,000 after acquiring an additional 324,293 shares during the period. Wasatch Advisors LP boosted its stake in shares of Medpace by 14.0% during the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock worth $296,853,000 after acquiring an additional 116,354 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Medpace by 3.8% during the 4th quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock valued at $374,836,000 after acquiring an additional 24,625 shares during the period. Finally, Invesco Ltd. grew its position in shares of Medpace by 18.9% during the 3rd quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock valued at $276,313,000 after acquiring an additional 85,517 shares during the period. Institutional investors and hedge funds own 77.98% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the company. Jefferies Financial Group cut Medpace from a “buy” rating to a “hold” rating and upped their price target for the stock from $490.00 to $515.00 in a report on Tuesday, July 7th. Robert W. Baird boosted their price objective on Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a research report on Friday, July 24th. Mizuho upped their target price on Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $535.00 target price on shares of Medpace in a research report on Thursday, July 23rd. Finally, Weiss Ratings raised shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 12th. Three analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $584.18.

Medpace Trading Down 1.2%

Shares of Medpace stock opened at $611.57 on Friday. The firm has a market capitalization of $17.07 billion, a PE ratio of 35.85, a P/E/G ratio of 2.76 and a beta of 1.15. Medpace Holdings, Inc. has a twelve month low of $373.00 and a twelve month high of $677.90. The firm’s 50-day moving average price is $562.52 and its 200 day moving average price is $493.80.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. During the same period in the previous year, the business earned $3.10 EPS. Medpace’s quarterly revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, sell-side analysts predict that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Insider Transactions at Medpace

In related news, Director Brian T. Carley sold 5,000 shares of the stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $608.63, for a total value of $3,043,150.00. Following the completion of the transaction, the director directly owned 27,825 shares of the company’s stock, valued at approximately $16,935,129.75. This represents a 15.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Kevin M. Brady sold 3,400 shares of the firm’s stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $625.24, for a total value of $2,125,816.00. Following the completion of the transaction, the chief financial officer owned 12,830 shares in the company, valued at $8,021,829.20. The trade was a 20.95% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 129,963 shares of company stock valued at $79,364,624. Insiders own 20.50% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.